The Indian Journal of Pediatrics

, Volume 68, Issue 7, pp 641–647 | Cite as

Antiretroviral drugs in pediatrics

Symposium on Antimicrobials—I


The advent of potent drugs to treat HIV and the development of increasingly effective treatment strategies have resulted in dramatic improvements in the prognosis and quality of life for HIV-infected children. The purpose of this article is to provide the primary care physicians with practical information on antiretroviral drugs that are currently used for the treatment of pediatric HIV infection.

Key words

Antiretrovirals HIV Pediatrics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Working Group on Antiretroviral Agents in Pediatric HIV Infection. Guidelines for the use of antiretroviral agents in pediatric HIV infection. January 7, 2000. Website: http://www.hivatis.orgGoogle Scholar
  2. 2.
    Cohen-Stuart JW, Slieker WA, Rijkers GTet al. Early recovery of CD4+T lymphocytes in children on highly active antiretroviral therapy.AIDS 1998;2:2155–2159.CrossRefGoogle Scholar
  3. 3.
    Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1.Pediatr Infect Dis J 1999;18:682–689.PubMedCrossRefGoogle Scholar
  4. 4.
    Krogstad P, Wiznia A, Luzuriaga Ket al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate.Clin Infect Dis 1999;28:1109–1118.PubMedCrossRefGoogle Scholar
  5. 5.
    Starr SE, Fletcher CV, Spector SAet al. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1.N Engl J Med 1999;341:1874–1881.PubMedCrossRefGoogle Scholar
  6. 6.
    de Martino M, Tovo P, Balducci Met al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection.JAMA 2000; 284:190–197.PubMedCrossRefGoogle Scholar
  7. 7.
    Nachman S, Stanley K, Yogev Ret al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial.JAMA 2000;283:492–498.PubMedCrossRefGoogle Scholar
  8. 8.
    Connor EM, Sperling RS, Gelber Ret al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment.N Engl J Med 1994;331:1173–1180.PubMedCrossRefGoogle Scholar
  9. 9.
    Shaffer N, Chuachoowong R, Mock PAet al. Shortcourse zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: a randomised controlled trial.Lancet 1999;353:773–780.PubMedCrossRefGoogle Scholar
  10. 10.
    Brinkman K, ter Hofstede HJ, Burger DM, Smeitink JA, Koopmans PP Adverse effect of reverse transcriptase inhibitors: mitochondrial toxicity as a common pathway.AIDS 1998;12:1735–1744.PubMedCrossRefGoogle Scholar
  11. 11.
    Fischl M, Greenberg S, Clumeck Net al. Safety and activity of abacavir with 3TC/ZDV in antiretroviralnaïve subjects [abstract 127/12230]. Presented at: The 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland.Google Scholar
  12. 12.
    Kline MW, Blanchard S, Fletcher CVet al. A phase I study of abacavir (1592U89) alone and in combination with other antiretroviral, agents in infants and children with human immunodeficiency virus infection.Pediatrics 1999;103:e47.PubMedCrossRefGoogle Scholar
  13. 13.
    Guay LA, Musoke P, Fleming Tet al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial.Lancet 1999;354:795–802.PubMedGoogle Scholar
  14. 14.
    Cadman J. Efavirenz pregnancy warning.Treatment Issues 1998;12:No 3.Google Scholar
  15. 15.
    Carr A, Samaras K, Burton Set al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving protease inhibitors.AIDS 1998;12:F51-F58.PubMedCrossRefGoogle Scholar
  16. 16.
    Tsiodras S, Mantzoros C, Hammer S, Samore M. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.Arch Intern Med. 2000;160:2050–2056.PubMedCrossRefGoogle Scholar
  17. 17.
    Jaquet D, Lévine M, Ortega-Rodriguez Eet al. Clinical and metabolic presentation of lipodystrophic syndrome in HIV-infected children.AIDS 2000;14:2123–2128.PubMedCrossRefGoogle Scholar
  18. 18.
    Wiznia A, Stanley K, Krogstad Pet al. Combination nucleoside analogues plus nelfinavir, nevirapine or ritonavir in stable antiretroviral therapy-experienced HIV-infected children [Abstract 697]. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, USA.Google Scholar
  19. 19.
    Hsu A, Granneman G, Chen Set al. Assessment of single- and multiple-dose interactions between ritonavir and saquinavir [abstract LB.B.6041]. Presented at: XIII International AIDS Conference; July 9–14, 2000; Durban, South Africa.Google Scholar
  20. 20.
    Van Heeswijk R, Veldkemp A, Hoetelmans Ret al. The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.AIDS 1999;13:F95-F99.PubMedCrossRefGoogle Scholar
  21. 21.
    Kopp JB, Miller KD, Mican JAet al. Crystalluria and urinary tract abnormalities associated with indinavir.Ann Intern Med 1997;127:119–125.PubMedGoogle Scholar
  22. 22.
    Mueller BU, Sleasman J, Nelson RPet al. A phase I/II study of the protease inhibitor indinavir in children with HIV infection.Pediatrics 1998;102:101–109.PubMedCrossRefGoogle Scholar
  23. 23.
    Reiter WJ, Schon-Pernerstorfer H, Dorfinger K, Hofbauer J, Marberger M. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed.J Urol 1999;161:1082–1084.PubMedCrossRefGoogle Scholar
  24. 24.
    Church J, Rathore M, Rubio Tet al. A phase III study of amprenavir in protease-inhibitor-naïve and-experienced HIV-infected children and adolescents. Presented at: The 7th Conference on Retroviruses and Opportunistic Infections; January 30–February 2, 2000; San Francisco, USA.Google Scholar
  25. 25.
    Schmidt B, Korn K, Moschik Bet al. Low level of crossresistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors. Antimicrob Agents Chemother 2000; 44:3213–3216.PubMedCrossRefGoogle Scholar
  26. 26.
    Hsu A, Isaacson J, Kempf Det al. Trough concentation-EC50 relationship as a predictor of viral response for ABT-378/ritonavir in treatment-experienced patients [abstract 171]. Presented at: The 40th Interscience Conference on Antimicrobial Agent and Chemotherapy; September 17–20, 2000; Toronto, Canada.Google Scholar

Copyright information

© Dr. K C Chaudhuri Foundation 2001

Authors and Affiliations

  1. 1.Division of Infectious Diseases, Children's Hospital of MichiganWayne State University School of MedicineDetroitUSA

Personalised recommendations